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Background
The ATP-binding cassette (ABC) transporters breast
cancer resistance protein (BCRP) and P-glycoprotein
(P-gp) are expressed in the blood-brain barrier (BBB),
where they impede brain uptake of their substrates by
active efflux transport. BCRP has recently been shown
to be the quantitatively most important ABC transporter
at the human BBB. Inhibition of BCRP by inhibitors
such as the fumitremorgin C derivative Ko143 [1] may
be an interesting strategy to improve brain uptake of
BCRP substrates. The aim of this study was to assess
the dose-response relationship of Ko143 for inhibition
of Bcrp1 at the murine BBB using small-animal positron
emission tomography (PET) together with the dual
P-gp/BCRP substrate radiotracer [
11C]tariquidar.
Methods
[
11C]Tariquidar PET scans were performed in female
wild-type (FVB), Bcrp1
−/− and Mdr1a/b
−/− mice before
and 60 min after i.v. injection of Ko143 (Axon Med-
chem BV, The Netherlands) at a dose of 5 mg/kg. Addi-
tionally, in Mdr1a/b
−/− mice scans were performed after
i.v. administration of vehicle (n = 2), 1 mg/kg (n = 2),
3 mg/kg (n = 1), 10 mg/kg (n = 3) and 15 mg/kg (n =
2) of Ko143. After the 60-min PET scans a venous
blood sample was taken by retro-orbital puncture.
Brains were manually outlined on the reconstructed
PET images and time-activity curves expressed as
percent injected dose per gram (%ID/g) were generated,
for which areas under the curve (AUC) were calculated.
Results
Wild-type and Bcrp1
−/− mice showed no increase in
brain AUCs after administration of 5 mg/kg Ko143 as
compared to baseline scans, whereas in Mdr1a/b
−/−
mice brain AUC was 4.5-fold increased. In Mdr1a/b
−/−
mice, the half-maximum effect dose of Ko143 to
increase brain AUC of [
11C]tariquidar was 5.6 ± 2.3 mg/
kg. Maximum increase in brain AUC was 8.2-fold after
the 15 mg/kg dose. No changes in blood activity con-
centrations of [
11C]tariquidar were found after adminis-
tration of different Ko143 doses.
Conclusions
Performing PET scans in Mdr1a/b
(-/-) mice in combina-
tion with the dual P-gp/BCRP substrate [
11C]tariquidar
allowed individual assessment of Bcrp1 inhibition at the
BBB. Our data demonstrate that Ko143 is a potent inhi-
bitor of cerebral Bcrp1 in vivo, which apparently does
not inhibit P-gp at the studied doses.
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